国产吉西他滨联合卡铂治疗晚期非小细胞肺癌的临床观察

Combined chemotherapy with domestic gemcitabine plus carboplatin in the treatment of advanced non-small cell lung cancer

背景与目的 化疗在晚期非小细胞肺癌的治疗中具有极为重要的作用。本研究的目的是观察国产吉西他滨（泽菲）联合卡铂治疗晚期非小细胞肺癌的近期疗效、临床受益和毒副反应。方法 对34例初治的晚期（ⅢB及Ⅳ期）非小细胞肺癌患者给予国产吉西他滨联合卡铂治疗。卡铂AUC5，第1天；吉西他滨1000mg／m^2，第1、8天，静脉滴注。21天为一个周期，每例患者治疗3～4周期。结果 34例患者临床有效率（完全缓解＋部分缓解）为44％（15／34），总的临床受益反应率为53％（18／34）。主要毒副反应为血液学毒性，Ⅲ～Ⅳ度白细胞和血小板下降发生率分别为47％和24％，其余毒副反应较轻，可耐受。结论 国产吉西他滨联合卡铂治疗初治的晚期非小细胞肺癌有较好的疗效，毒性反应可以耐受。

Background and objective Chemotherapy is very important in the treatment of advanced nonsmall cell lung cancer （NSCLC）. The aim of this study is to evaluate the efficacy, clinical benefit and toxicity of combined chemotherapy with domestic gemcitabine （ZEFEI） plus carboplatirt in the treatment of advanced NSCLC. Methods Thirty-four previously untreated patients with advanced NSCLC （stage Ⅲ-Ⅳ） received domestic gemcitahine of 1000 mg/m^2 on days 1, 8, and carhoplatin of AUC 5 on day 1, with 21 days as a cycle. Each patient received at least three cycles. Results The total clinical response rate （complete and partial response） was 44 % （15/34）. Overall clinical benefit rate was 53% （18/34）. The main toxicities were hematological toxicities. The rate of grade Ⅲ-Ⅳ leukopenia and thromhocytopenia was 47% and 24 % respectively. Conclusion Combined chemotherapy with domestic gemcitabine plus carhoplatin is an effective and feasible regimen for advanced NSCLC.